EPS for Sangamo Therapeutics, Inc. (SGMO) Expected At $-0.20; Stampscom (STMP) Has 1.42 Sentiment

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Stampscom Inc (STMP) investors sentiment increased to 1.42 in Q3 2018. It’s up 0.24, from 1.18 in 2018Q2. The ratio is more positive, as 156 active investment managers started new and increased stock positions, while 110 decreased and sold holdings in Stampscom Inc. The active investment managers in our database reported: 15.92 million shares, up from 15.64 million shares in 2018Q2. Also, the number of active investment managers holding Stampscom Inc in top ten stock positions decreased from 7 to 1 for a decrease of 6. Sold All: 30 Reduced: 80 Increased: 89 New Position: 67.

Analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report $-0.20 EPS on February, 28.They anticipate $0.05 EPS change or 33.33% from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, Sangamo Therapeutics, Inc.’s analysts see 53.85% EPS growth. The stock increased 0.11% or $0.01 during the last trading session, reaching $8.96. About 942,046 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 32.09% since February 13, 2018 and is downtrending. It has underperformed by 32.09% the S&P500. Some Historical SGMO News: 16/05/2018 – Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease; 04/04/2018 – Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS Il In Vivo Genome Editing Program; 16/05/2018 – BIOVERATIV & SANGAMO REPORT FDA ACCEPTANCE OF IND APPLICATION; 24/04/2018 – Sangamo Therapeutics Plans $200 Million Share Offering; 01/05/2018 – Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy; 16/05/2018 – SANGAMO THERAPEUTICS – IND ENABLES BIOVERATIV TO INITIATE PHASE 1/2 CLINICAL TRIAL TO ASSESS SAFETY OF BIVV003 IN ADULTS WITH SICKLE CELL DISEASE; 08/05/2018 – SANGAMO 1Q LOSS/SHR 23C, EST. EPS 25C; 24/04/2018 – SANGAMO THERAPEUTICS FILES MIXED SECURITIES SHELF; 24/04/2018 – Sangamo Therapeutics Announces Proposed Public Offering of Common Stk; 16/05/2018 – Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell

Since August 16, 2018, it had 3 buys, and 10 sales for $491,339 activity. Another trade for 7,408 shares valued at $100,487 was made by JEFFS ROGER on Friday, September 7. Conner Edward R. sold 5,000 shares worth $68,650. Another trade for 5,000 shares valued at $57,200 was sold by Yi Kathy. PARKER H STEWART also bought $27,040 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Friday, September 7.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Benzinga.com which released: “Sangamo (NASDAQ:SGMO) Fails To Impress Investors With Genome Editing Studies – Benzinga” on February 07, 2019, also Nasdaq.com with their article: “Week Ahead In Pharmaceuticals: 6 Stocks To Watch (EOLS, AVRO, SGMO…) – Nasdaq” published on February 01, 2019, Nasdaq.com published: “Mid-Afternoon Market Update: Dow Down 1.1%; Chipotle Shares Jump Following Upbeat Q4 Results – Nasdaq” on February 07, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” published on February 01, 2019 as well as Prnewswire.com‘s news article titled: “Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development – PRNewswire” with publication date: January 22, 2019.

Among 2 analysts covering Sangamo Therapeutics (NASDAQ:SGMO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Sangamo Therapeutics had 2 analyst reports since November 9, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Guggenheim on Friday, November 9. On Wednesday, November 14 the stock rating was downgraded by JP Morgan to “Neutral”.

Investors sentiment decreased to 1.25 in 2018 Q3. Its down 0.19, from 1.44 in 2018Q2. It worsened, as 20 investors sold Sangamo Therapeutics, Inc. shares while 49 reduced holdings. 35 funds opened positions while 51 raised stakes. 59.55 million shares or 0.59% less from 59.91 million shares in 2018Q2 were reported. Proshare Advisors Ltd Liability holds 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 53,866 shares. Advisory Service Limited Liability Com invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Clarivest Asset Ltd Limited Liability Company owns 0.03% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 116,248 shares. Strs Ohio reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Goldman Sachs invested in 0% or 1.11M shares. Riverhead Capital Mngmt Ltd Com reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Northern Corporation, a Illinois-based fund reported 1.32M shares. Guggenheim Capital Limited Liability has invested 0.02% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Moreover, Stratos Wealth Partners has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 3,754 shares. 3,000 were reported by Nelson Roberts Investment Advsr Ltd Liability Corp. Fmr Llc has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tocqueville Asset Lp accumulated 711,237 shares. 5,235 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Adage Capital Partners Group Incorporated Lc reported 1.40M shares. Sector Gamma As reported 0.39% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $914.75 million. The company's zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

More notable recent Stamps.com Inc. (NASDAQ:STMP) news were published by: Nasdaq.com which released: “Noteworthy Monday Option Activity: DFRG, TWLO, STMP – Nasdaq” on February 11, 2019, also Nasdaq.com with their article: “Commit To Buy Stamps.com At $95, Earn 7.3% Using Options – Nasdaq” published on February 06, 2019, Seekingalpha.com published: “Stamps.com reports Q3 beats, raises FY guide – Seeking Alpha” on October 31, 2018. More interesting news about Stamps.com Inc. (NASDAQ:STMP) were released by: Nasdaq.com and their article: “Why Stamps.com Stock Just Dropped 8% – Nasdaq” published on October 17, 2018 as well as Seekingalpha.com‘s news article titled: “Stamps.com Is Interesting – Seeking Alpha” with publication date: October 18, 2018.

Stamps.com Inc. provides Internet-based mailing and shipping solutions in the United States. The company has market cap of $3.56 billion. The firm offers mailing and shipping solutions to mail and ship various mail pieces and packages through the United States Postal Service under the Stamps.com and Endicia brands. It has a 22.23 P/E ratio. The Company’s solutions support various USPS mail classes, including First Class Mail, Priority Mail, Priority Mail Express, Media Mail, Parcel Select, and others.

Since January 1, 0001, it had 0 buys, and 7 insider sales for $2.38 million activity.

Tekne Capital Management Llc holds 7.31% of its portfolio in Stamps.com Inc. for 124,771 shares. Hhr Asset Management Llc owns 326,765 shares or 4.26% of their US portfolio. Moreover, P2 Capital Partners Llc has 3.18% invested in the company for 156,500 shares. The California-based Cornerstone Capital Inc. has invested 3.04% in the stock. Shaker Investments Llc Oh, a Ohio-based fund reported 18,598 shares.

Stamps.com Inc. (NASDAQ:STMP) Institutional Positions Chart